Literature DB >> 19078409

Membranous obstruction of the inferior vena cava and extensive bone marrow necrosis associated with catastrophic antiphospholipid syndrome.

A C Spyropoulos1.   

Abstract

The catastrophic antiphospholipid syndrome is a rare and devastating manifestation of the antiphospholipid syndrome. It is associated with acute multi-organ failure involving three or more end organs in patients with antiphospholipid antibodies. A precipitating event can be found in some cases, and mortality rates have approached 60%. This article describes a case of catastrophic antiphospholipid syndrome in a patient who presented with Budd-Chiari syndrome from membranous obstruction of the inferior vena cava and extensive bone marrow necrosis shortly after a surgical procedure. These and other clinical manifestations of multi-organ failure (including low-grade disseminated intravascular coagulation) were associated with high titers of immunoglobulin M anticardiolipin antibodies. The patient fully recovered after being treated with percutaneous transluminal angioplasty and aggressive anticoagulation. The pathogenesis of catastrophic antiphospholipid syndrome in this patient may well have resulted from in situ thrombus formation around an intravascular coagulation web (congenital or acquired) from a patient predisposed to a hypercoagulable state from anticardiolipin antibodies and a recent surgical procedure.

Entities:  

Year:  1999        PMID: 19078409     DOI: 10.1097/00124743-199910000-00008

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  2 in total

1.  A case of antiphospholipid syndrome presenting cryptogenically as Budd-Chiari syndrome, then fulminantly as Libman-Sacks endocarditis.

Authors:  Hart A Goldhar; Paloma O'Meara; Lana A Castellucci
Journal:  BMJ Case Rep       Date:  2019-05-14

Review 2.  Orthopedic involvement in antiphospholipid syndrome.

Authors:  Alexander Gorshtein; Yair Levy
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.